Pharmacia & Upjohn

Last updated
Pharmacia & Upjohn
TypePublic
Industry Pharmaceutical
FoundedMerger of Pharmacia AB & The Upjohn Company
FateAcquired by Pfizer

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. [1] Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

Contents

History

Amersham

In 1997, the biotechnology division of the company Pharmacia Biotech merged with Amersham Life Science with the new merged entity being known as Amersham Pharmacia Biotech. [2] [3] In 2001, the company was renamed Amersham Biotech. [4] In 2002, Pharmacia sold its share of the company to Amersham plc. [5] [6] In 2004, Amersham Biosciences was acquired by GE Healthcare. [7]

In 1998, the nutrition division of the company was sold to Fresenius. [8]

Monsanto

Monsanto acquired the pharmaceutical company G. D. Searle & Company in 1985. [9] In 1998, Searle and the Monsanto Pharma Sector partnered with Pfizer to develop and promote celecoxib, an anti-inflammatory drug used to treat arthritis. [10] [11] Branded as Celebrex, celecoxib was approved by the FDA in 1998. [12] In December 1999, Pharmacia & Upjohn merged with the American biotechnology and medical company, Monsanto and renamed itself Pharmacia. [13] The company retained Monsanto's pharmaceutical division - then known as Searle - and spun off the remaining interests as the "new Monsanto". [14] [15] The newly merged pharmaceutical entity changed its name to Pharmacia Corp. [16]

Pfizer

In July 2002, Pharmacia Corp. and Pfizer announced an agreement that Pfizer would purchase Pharmacia; control of celecoxib was often mentioned as a key reason for Pfizer's acquisition of Pharmacia. [17] The deal was finalized in April 2003. [18]

Later developments

Overview

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Pharmacia Corp.
Acquired by  Pfizer, 2002

Pharmacia & Upjohn
Pharmacia
(Merged 1995)
Kabi Pharmacia
Pharmacia Biotech

LKB-produkter AB
(Acq 1968)

PL Laboratories

Kabi Vitrum
(Acq 1990)

Farmitalia
(Acq 1993)

Upjohn
(Merged 1995)

Monsanto

Monsanto

G. D. Searle & Company
(Acq 1985)

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

<span class="mw-page-title-main">Pharmacia</span> Pharmaceutical and biotechnological company

Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995.

<span class="mw-page-title-main">Celecoxib</span> Nonsteroidal anti-inflammatory drug

Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.

<span class="mw-page-title-main">Valdecoxib</span> Nonsteroidal anti-inflammatory drug

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995.

The NutraSweet Company is an American nutrient company that produces and markets NutraSweet Neotame, their trademarked brand name for the high-intensity sweetener neotame.

<span class="mw-page-title-main">Amersham plc</span> Former British radiopharmaceutical manufacturer

Amersham plc was a manufacturer of radiopharmaceutical products, to be used in diagnostic and therapeutic nuclear medicine procedures. The company became GE Healthcare following a takeover in 2003, which was based at the original site in Amersham, Buckinghamshire until 2016, when the headquarters moved to Chicago.

G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company. Searle is most notable for having developed the first female birth control pill, and the artificial sweetener NutraSweet. Searle also developed the drug Lomotil, an antidiarrheal medication. One of the notable Alumni of Searle is Donald Rumsfeld, the Secretary of Defense for Bush in the 2000s. Prior to its 1985 merger with Monsanto, Searle was a company mainly focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

<span class="mw-page-title-main">Upjohn</span> Pharmaceutical manufacturing firm

The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Hastings, Michigan, by Dr. William E. Upjohn who was an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. They could be "reduced to a powder under the thumb", a strong marketing argument at the time.

Co-promotion is a marketing practice that allows two or more companies to combine their sales force in order to promote a product under the same brand name and price with a single marketing strategy. It is considered as one of the two major forms of joint marketing. Co-marketing is the other form and these terms are often confused. It is made through an agreement which requires a lot of collaboration between the sales and marketing organisations of both companies. One of the partners usually has a licence to exploit the product and the other partner is the originator or licensor. It helps the less developed areas of a company to be covered by the partner company's strengths and therefore to expand the share of voice in the marketplace for a product. Through co-promotion, a collaborative strategy, the consumer attraction is increased. It is a way co-exploiting products.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

<span class="mw-page-title-main">Swedish Orphan Biovitrum</span> Swedish pharmaceutical company

Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.

Robert B. Shapiro is a businessman and attorney who has worked extensively with the biochemical corporations G. D. Searle & Company and Monsanto. Before working in this sector he was Vice-President and legal counsel at General Instrument from 1972 to 1979. His father, Moses, was Chairman of this company from 1969 to 1975.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 18 manufacturing plants, 15 in India and the rest in United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

References

  1. ↑ "Upjohn Company". 7 May 2006. Archived from the original on 2006-05-07.
  2. ↑ Newman, Cathy (1997-05-31). "Amersham close to life sciences merger". The Independent. Retrieved 2020-11-16.
  3. ↑ Stephen, Moore (1997-06-11). "Amersham Merges Division With Pharmacia & Upjohn". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-11-16.
  4. ↑ Basar, Shanny (12 March 2002). "Morgan Stanley and Hoare Govett sell £350m Amersham sale". Financial News London. Retrieved 2020-11-16.
  5. ↑ "Pharmacia Corp selling stake in Amersham Biosciences for $1 billion -". The Pharma Letter. 18 March 2002. Retrieved 2020-11-16.
  6. ↑ "Amersham buys out bioscience ally". the Guardian. 2002-03-13. Retrieved 2020-11-16.
  7. ↑ Rovito, Rich (8 April 2004). "GE completes acquisition of Amersham, restructures GE Healthcare". Milwaukee Business Journal.
  8. ↑ "INTERNATIONAL BRIEFS; Fresenius of Germany Buying Pharmacia Unit (Published 1998)". The New York Times. 1998-06-09. ISSN   0362-4331 . Retrieved 2020-11-16.
  9. ↑ Greenhouse, Steven (1985-07-19). "MONSANTO TO ACQUIRE G. D. SEARLE (Published 1985)". The New York Times. ISSN   0362-4331 . Retrieved 2020-11-16.
  10. ↑ "Monsanto's Searle unit developing arthritis drug with Pfizer". St. Louis Business Journal. 18 February 1998.
  11. ↑ Langreth, Robert (1998-02-19). "Pfizer to Help Searle Develop, Market Arthritis Drug in Race With Merck, J&J". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-11-16.
  12. ↑ "Fast Facts on Bextra and Celebrex". ABC News. 6 January 2006. Retrieved 2020-11-16.
  13. ↑ Stein, George; Chase; Brett (1999-12-20). "Pharmacia & Upjohn, Monsanto to Merge in $26.5-Billion Deal". Los Angeles Times. Retrieved 2020-11-16.
  14. ↑ "Monsanto Raises $700 Million in IPO". Los Angeles Times. October 18, 2000.
  15. ↑ "Monsanto and Pharmacia to Join, Creating a Pharmaceutical Giant", New York Times, December 20, 1999, retrieved 28 December 2015
  16. ↑ "Drug cos. to call new firm 'Pharmacia'". CNN Money. 27 January 2000. Retrieved 2020-11-16.
  17. ↑ Sorkin, Andrew (15 July 2002). "PFIZER SAID TO BUY LARGE DRUG RIVAL IN $60 BILLION DEAL". New York Times.
  18. ↑ "It's official: Pfizer buys Pharmacia". 16 April 2003.
  19. ↑ "Pharmacia Spins Off Metabolic Disease Business Into Biovitrum + | Bioworld" . BioWorld. 8 August 2001. Retrieved 2020-11-16.
  20. ↑ "COMPANY NEWS; PHARMACIA TO CREATE SEPARATE BIOTECHNOLOGY COMPANY (Published 2001)". The New York Times. 2001-01-13. ISSN   0362-4331 . Retrieved 2020-11-16.
  21. ↑ Sheridan, Cormac (3 July 2002). "Biovitrum Sells Off Plasma Business To Swiss Company + | Bioworld". BioWorld. Retrieved 2020-11-16.
  22. ↑ "Pfizer to Sell Diagnostics Unit To Two Firms for $575 Million". Wall Street Journal. 2004-01-20. ISSN   0099-9660 . Retrieved 2020-11-16.
  23. ↑ "Pfizer sells surgical ophalmics business for $450M - Pharmaceutical in" . The Pharma Letter. 25 April 2004. Retrieved 2020-11-16.
  24. 1 2 Parkinson, Gary (2006-09-18). "Phadia sale to deepen concerns over private equity debt". The Independent. Retrieved 2020-11-16.
  25. ↑ "Kemwell acquires Pfizer facility". New Europe. 2006-04-02. Retrieved 2020-11-16.
  26. ↑ Macdonald, Gareth (25 August 2009). "Pfizer inaugurates new $214m Swedish biotech plant". BioPharma Reporter. Retrieved 2020-11-16.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.